NO861409L - A PLASMINOGEN ACTIVATOR-CONTAINING AGENT. - Google Patents
A PLASMINOGEN ACTIVATOR-CONTAINING AGENT.Info
- Publication number
- NO861409L NO861409L NO861409A NO861409A NO861409L NO 861409 L NO861409 L NO 861409L NO 861409 A NO861409 A NO 861409A NO 861409 A NO861409 A NO 861409A NO 861409 L NO861409 L NO 861409L
- Authority
- NO
- Norway
- Prior art keywords
- plasminogen activator
- saccharide
- acid ester
- medicine according
- optionally
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title description 2
- 108010051456 Plasminogen Proteins 0.000 title description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 14
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 14
- 229940127126 plasminogen activator Drugs 0.000 claims description 14
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 13
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000047823 human PLAT Human genes 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 description 2
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
Oppfinnelsen vedrører et legemiddel inneholdende en vev-plasminogenaktivator eller et av dets naturlige forekommende, syntetisk eller genteknisk fremstilte derivater. The invention relates to a medicinal product containing a tissue plasminogen activator or one of its naturally occurring, synthetic or genetically engineered derivatives.
Gruppen omfattende vev-plasminogenaktivator (t-PA) og dets naturlig forekommende, syntetisk eller genteknisk fremstilte derivater betegnes her som plasminogenaktivatorer (PA). Plasminogen omdannes ved plasminogenaktivatorer til plasmin. Til katalysatorene av denne reaksjon fører Streptokinase, Urokinase og t-PA. Den terapeutiske anvendelse av disse aktivatorer som fibrinolytika er kjent. På grunn av dets høye affinitet til fibrin er t-PA av spesiell betydning for lyse-terapien. The group comprising tissue plasminogen activator (t-PA) and its naturally occurring, synthetic or genetically engineered derivatives are referred to herein as plasminogen activators (PA). Plasminogen is converted to plasmin by plasminogen activators. Streptokinase, Urokinase and t-PA lead to the catalysts of this reaction. The therapeutic use of these activators as fibrinolytics is known. Because of its high affinity to fibrin, t-PA is of particular importance for lysis therapy.
Til grunn for oppfinnelsen ligger den oppgave å fremstilleThe invention is based on the task of producing it
et PA-preparat som er mer virksomt enn ren vev-plasminogenaktivator . a PA preparation that is more effective than pure tissue plasminogen activator.
Det ble overraskende funnet at ovenfor definerte plasminogenaktivatorer (PA) har en høy affinitet til polysvovelsyreestere av sakkarider eller sulfaterte sukkere og at aktivi-teten av PA er øket i nærvær av en polysvovelsyreester av et sakkarid eller sulfatert sukker. It was surprisingly found that the above-defined plasminogen activators (PA) have a high affinity for polysulfuric acid esters of saccharides or sulfated sugars and that the activity of PA is increased in the presence of a polysulfuric acid ester of a saccharide or sulfated sugar.
Oppfinnelsens gjenstand er følgelig et legemiddel inneholdende en blanding av en plasminogenaktivator fra gruppen bestående av vev-plasminogenaktivator og dets naturlig forekommende, syntetisk eller genteknisk fremstilte derivater (PA) og en polysvovelsyreester av et sakkarid eller sulfatert sukker. The object of the invention is therefore a medicinal product containing a mixture of a plasminogen activator from the group consisting of tissue plasminogen activator and its naturally occurring, synthetically or genetically engineered derivatives (PA) and a polysulphuric acid ester of a saccharide or sulfated sugar.
Et slikt legemiddel anvendes fortrinnsvis til behandling av tromboser og embolier. Such a drug is preferably used for the treatment of thrombosis and embolism.
Fortrinnsvis inneholder et slikt legemiddel en PA og en polysvovelsyreester av et sakkarid eller sulfatert sukker i et molart forhold på 10:1 til 1:100.000, fortrinnsvis 10:1 til 1:10.000. Preferably, such a drug contains a PA and a polysulphuric acid ester of a saccharide or sulfated sugar in a molar ratio of 10:1 to 1:100,000, preferably 10:1 to 1:10,000.
Bindingen av t-PA til polysvovelsyreestere av sakkariderThe binding of t-PA to polysulfuric acid esters of saccharides
eller sulfaterte sukkere kunne vises ved hjelp av immunelektro-forese. T-PA ble inkubert med heparin, heparan-sulfat, anteparon, dekstran-sulfat eller pentosan-sulfat og undersøkt immunelektroforetisk. Båndene av en med en polysvovelsyreester av et sakkarid eller sulfatert sukker inkubert t-PA forskjøv seg i anodisk retning, mens t-PA forble fast på påføringsstedet. or sulfated sugars could be shown by immunoelectrophoresis. T-PA was incubated with heparin, heparan sulfate, anteparone, dextran sulfate, or pentosan sulfate and examined immunoelectrophoretically. The bands of a t-PA incubated with a polysulfuric acid ester of a saccharide or sulfated sugar shifted in the anodic direction, while the t-PA remained fixed at the site of application.
Oppfinnelsens gjenstand er også en fremgangsmåte til frem-r stilling av et slikt legemiddel, idet fremgangsmåten erkarakterisert vedat t-PA eller et av dens naturlig forekommende, syntetisk eller genteknisk fremstilte derivater blandes med en polysvovelsyreester av et sakkarid eller sulfatert sukker, fortrinnsvis i et molart forhold på 10:1 The object of the invention is also a method for the preparation of such a drug, the method being characterized in that t-PA or one of its naturally occurring, synthetically or genetically engineered derivatives is mixed with a polysulphuric acid ester of a saccharide or sulfated sugar, preferably in a molar ratio of 10:1
til 1:100.000, spesielt foretrukket i et forhold på 10:1to 1:100,000, particularly preferred in a ratio of 10:1
til 1:10.000, og eventuelt en stabilisator, eventuelt ad-skilles overskuddet av den anvendte polysvovelsyreester eller sulfatert sukker og eventuelt frysetørkes. to 1:10,000, and optionally a stabilizer, optionally the excess of the used polysulphuric acid ester or sulfated sugar is separated and optionally freeze-dried.
Som stabilisator kan det anvendes eksempelvis albumin, gela-tiner eller et avbygget, kjemisk kryssbundet kollagen eller et slikt gelatin. As a stabilizer, for example, albumin, gelatins or a denatured, chemically cross-linked collagen or such a gelatin can be used.
Claims (8)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853512908 DE3512908A1 (en) | 1985-04-11 | 1985-04-11 | TISSUE-PLASMINOGEN ACTIVATOR (T-PA) CONTAINING AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861409L true NO861409L (en) | 1986-10-13 |
Family
ID=6267672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861409A NO861409L (en) | 1985-04-11 | 1986-04-10 | A PLASMINOGEN ACTIVATOR-CONTAINING AGENT. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0198321A1 (en) |
| JP (1) | JPS61236730A (en) |
| AU (1) | AU5595486A (en) |
| DE (1) | DE3512908A1 (en) |
| DK (1) | DK162086A (en) |
| ES (1) | ES8800599A1 (en) |
| IL (1) | IL78450A0 (en) |
| NO (1) | NO861409L (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2520975B2 (en) * | 1989-09-21 | 1996-07-31 | 三井東圧化学株式会社 | Thrombolytic agent containing tissue plasminogen activator or its derivative |
| JPH0791318B2 (en) * | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | Aqueous protein solution, method for increasing concentration of aqueous protein solution, and protein preparation |
| JP2007501223A (en) * | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー．ブイ． | Use of recombinant or synthetic gelatin as a stabilizer in vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2310133A2 (en) * | 1975-05-05 | 1976-12-03 | Fabre Sa Pierre | NEW MEDICINAL PRODUCT CONTAINING AN IMPROVED PLASMINOGEN ACTIVATOR |
| CH630661A5 (en) * | 1978-01-01 | 1982-06-30 | Fabre Sa Pierre | Process for the production of a medicinal composition containing a plasminogen activator and a sulphated polysaccharide |
| FR2483234A2 (en) * | 1980-05-29 | 1981-12-04 | Fabre Sa Pierre | OPHTHALMIC COMPOSITION CONTAINING A PLASMINOGEN ACTIVATOR |
-
1985
- 1985-04-11 DE DE19853512908 patent/DE3512908A1/en not_active Withdrawn
-
1986
- 1986-04-02 EP EP86104475A patent/EP0198321A1/en not_active Withdrawn
- 1986-04-08 IL IL78450A patent/IL78450A0/en unknown
- 1986-04-09 ES ES553802A patent/ES8800599A1/en not_active Expired
- 1986-04-10 DK DK162086A patent/DK162086A/en not_active IP Right Cessation
- 1986-04-10 NO NO861409A patent/NO861409L/en unknown
- 1986-04-10 JP JP61081248A patent/JPS61236730A/en active Pending
- 1986-04-10 AU AU55954/86A patent/AU5595486A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK162086A (en) | 1986-10-12 |
| DE3512908A1 (en) | 1986-10-23 |
| ES553802A0 (en) | 1987-11-16 |
| JPS61236730A (en) | 1986-10-22 |
| IL78450A0 (en) | 1986-08-31 |
| AU5595486A (en) | 1986-11-06 |
| ES8800599A1 (en) | 1987-11-16 |
| DK162086D0 (en) | 1986-04-10 |
| EP0198321A1 (en) | 1986-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cercek et al. | Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. | |
| US5084273A (en) | Composition of anticoagulants | |
| CA2129660A1 (en) | Tissue plasminogen activator glycosylation variants with improved therapeutic properties | |
| AU2036188A (en) | New tissue plasminogen activator | |
| DE4411143C2 (en) | Thrombotic agents | |
| Novokhatny et al. | Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis | |
| ATE107960T1 (en) | VARIANTS OF HUMAN TISSUE PLASMINOGEN ACTIVATOR AND METHODS FOR THEIR PRODUCTION. | |
| Pollak et al. | Ancrod causes rapid thrombolysis in patients with acute stroke | |
| AU3744889A (en) | Variants of plasminogen activators and processes for their production | |
| NO861409L (en) | A PLASMINOGEN ACTIVATOR-CONTAINING AGENT. | |
| DE3804600A1 (en) | MIXTURE OF A THROMBOLYTICALLY ACTIVE AND ANTITHROMBOTIC SUBSTANCE | |
| EP0098814A1 (en) | Antithrombin-heparin complex | |
| Tranchesi Jr et al. | Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction | |
| Grossbard | Recombinant tissue plasminogen activator: a brief review | |
| CA1303987C (en) | Pharmaceutical composition having thrombolytic activity | |
| Gaffhey | Tissue plasminogen activator for thrombolytic therapy: expectation versus reality | |
| US5174994A (en) | Pharmaceutical composition having thrombolytic activity | |
| EP0400545B1 (en) | Derivative of tissue plasminogen activator | |
| EP0352897B1 (en) | Tpa-containing medicaments | |
| EP0226172B1 (en) | Agent for the treatment of thrombosis consisting of a plasmin inhibitor and a plasminogen activator | |
| Verstraete et al. | Drugs affecting blood coagulation and hemostasis | |
| JPS604718B2 (en) | Stable urokinase composition and method for producing the same |